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Abstract. Background: D-dimer is related to adverse outcomes in arterial and venous thromboembolic diseases.
Objectives: To evaluate the predictive value of D-dimer
level for stroke, other cardiovascular events, and bleeds,
in patients with atrial fibrillation (AF) treated with oral
anticoagulation with apixaban or warfarin; and to evaluate the relationship between the D-dimer levels at baseline
and the treatment effect of apixaban vs. warfarin. Methods: In the ARISTOTLE trial, 18 201 patients with AF
were randomized to apixaban or warfarin. D-dimer was
analyzed in 14 878 patients at randomization. The cohort
was separated into two groups; not receiving vitamin K
antagonist (VKA) treatment and receiving VKA treatment at randomization. Results: Higher D-dimer levels
were associated with increased frequencies of stroke or
systemic embolism (hazard ratio [HR] [Q4 vs. Q1] 1.72,
95% confidence interval [CI] 1.14–2.59, P = 0.003),
death (HR [Q4 vs. Q1] 4.04, 95% CI 3.06–5.33) and
major bleeding (HR [Q4 vs. Q1] 2.47, 95% CI 1.77–3.45,
P < 0.0001) in the no-VKA group. Similar results were
obtained in the on-VKA group. Adding D-dimer level to
the CHADS2 score improved the C-index from 0.646 to
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0.655 for stroke or systemic embolism, and from 0.598 to
0.662 for death, in the no-VKA group. D-dimer level
improved the HAS-BLED score for prediction of major
bleeds, with an increase in the C-index from 0.610 to
0.641. There were no significant interactions between efficacy and safety of study treatment and D-dimer level.
Conclusion: In anticoagulated patients with AF, the level
of D-dimer is related to the risk of stroke, death, and
bleeding, and adds to the predictive value of clinical risk
scores. The benefits of apixaban were consistent, regardless of the baseline D-dimer level.
Keywords: apixaban; atrial fibrillation; D-dimer; risk
assessment; warfarin.

Introduction
Atrial fibrillation (AF) is associated with an increased risk
of stroke and systemic embolism (SEE) and death [1,2].
Oral anticoagulant treatment with vitamin K antagonist
(VKA) reduces the risk of stroke more effectively than
antiplatelet therapy, but less effectively than some of the
newer oral anticoagulants [3–5]. The currently established
tools for balancing the benefits of stroke prevention and
the bleeding risk during anticoagulant treatment are
based on clinical risk scores such as CHADS2/CHA2DS2VASc and HAS-BLED [6–10]. As most clinical risk factors have similar relationships to both thromboembolic
and bleeding events, and reflect vascular disease risk factors as opposed to thrombus in the left atrial appendage,
the tailoring of treatment to an individual patient is
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challenging, and might be improved by the addition of
information from biomarkers [11–13]. D-dimer is formed
upon degradation of fibrin, and reflects thrombin generation and fibrin turnover [14]. The D-dimer level is a clinically useful tool for the diagnosis of venous
thromboembolism, is a risk marker for recurrences after
cessation of anticoagulant treatment, and is associated
with thrombotic complications in patients with cancer
[15–17]. D-dimer levels are increased in patients with AF,
and high levels are associated with left atrial appendage
thrombus [18–20]. Warfarin treatment reduces D-dimer
levels, but the relationship between quality of control of
warfarin treatment (i.e. International Normalized Ratio
[INR] levels) and D-dimer level has varied in different
studies [21–23]. Apixaban, an oral direct factor Xa inhibitor, has been found to reduce D-dimer levels in patients
with venous thromboembolism and acute coronary syndrome [24,25]. In the ARISTOTLE trial on patients with
AF and at increased risk of stroke, anticoagulant treatment with apixaban as compared with warfarin reduced
the rates of stroke and SEE, all-cause mortality, and
bleeding [5]. In this study, we evaluated D-dimer level as
an independent risk factor for stroke and other non-fatal
and fatal cardiovascular events and for bleeding. We also
assessed the effects of randomized treatment on outcomes
in relation to D-dimer level at baseline.

non-major bleeding was defined as clinically overt bleeding that did not fulfill the criteria for major bleeding but
that led to hospital admission, physician-guided treatment, or a change in the oral antithrombotic treatment.
All clinical events were classified by a blinded clinical
event committee using prespecified criteria [27]. CHADS2,
CHA2DS2-VASc and HAS-BLED scores were calculated
individually for each patient on the basis of the sum of
risk factors present at randomization. Patients were categorized by CHADS2 according to scores of 0–1, 2, and
≥ 3, by CHA2DS2-VASc according to scores of 0–1, 2, 3,
4, and ≥ 5, and by HAS-BLED according to scores of
0–1, 2, and ≥ 3.

Patients and methods

Statistical analyses

The ARISTOTLE trial

The details of the ARISTOTLE trial have been published
previously [5,9]. Briefly, ARISTOTLE was a double-blind,
double-dummy, randomized clinical trial that enrolled
patients with AF and at least one CHADS2 risk factor
for stroke or SEE. Patients were randomly assigned
(1 : 1) to receive either warfarin (target international normalized ratio [INR] of 2.0–3.0) or apixaban (5 mg twice
daily). The number of patients included in the trial was
18 201, and the median follow-up was 1.8 years. The primary endpoint was stroke or SEE, and the primary safety
outcome was major bleeds according to the classification
of the ISTH [26].
Clinical endpoints and risk factor classification

The endpoints included stroke, defined as a neurologic
deficit that lasted for at least 24 h and subclassified as
ischemic (with or without hemorrhagic conversion), hemorrhagic, or uncertain, death from all causes, cardiac
death excluding fatalities caused by bleeding and non-cardiac causes, and myocardial infarction (MI). Major
bleeding was defined as clinically overt bleeding with a
decrease in hemoglobin level of at least 2 g L 1 or transfusion of two or more units of packed red cells, occurring
at a critical site, or resulting in death. Clinically relevant

Biochemical analysis

At randomization, blood samples for core laboratory
analyses of prespecified biomarkers were obtained from
14 878 patients. After centrifugation at 2000 9g for 15
min, platelet-poor plasma was stored at
80 °C until
analysis. D-dimer was centrally analyzed with a quantitative method; ELISA (Asserachrome; Stago, Asnieressur-Seine, France) in the Uppsala Clinical Research
Center (UCR) laboratory, Sweden. The reference limit of
normal was ≤ 500 lg L 1. The intra-assay coefficient of
variance was 11%.

The analyses included the 14 878 patients with available
D-dimer results at baseline before randomization to study
treatment. The median follow-up time was 1.9 years in
the D-dimer cohort. Anticoagulant treatment influences
coagulation activity and D-dimer levels [19]. Therefore,
the patient cohort was stratified into two groups: no
VKA, defined as not treated with oral anticoagulant
agents within the last week prior to randomization or
study entry (n = 6867); and on VKA, defined as treated
with oral anticoagulant treatment within the last 7 days
(n = 7982). In 29 of 14 878 patients, there was no information regarding the last dose of anticoagulant treatment, and these patients were therefore excluded from the
analyses. D-dimer levels were compared between VKA
groups by use of the Wilcoxon signed rank test. Demographics and other baseline characteristics were summarized by the use of frequencies for categorical variables
and median and 25th and 75th percentiles for continuous
variables. For tests among groups, the chi-square test was
used for categorical variables and the Kruskal–Wallis test
was used for continuous variables.
Efficacy analyses included all randomized patients and
all events from randomization until the efficacy cut-off date
(predefined as 30 January 2011). Bleeding analyses were
‘on treatment’, including all randomized patients who
received at least one dose of study drug, and included all
events from receipt of the study drug until 2 days after the
© 2014 International Society on Thrombosis and Haemostasis
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last dose of the study drug. The incidence rates of the different endpoints were summarized in relation to VKA
treatment, quartiles of D-dimer levels, and CHADS2,
CHA2DS2-VASc or HAS-BLED scores, as outlined above.
The relationships between D-dimer levels and outcomes
were evaluated both in simple and in adjusted Cox regression analysis. The adjusted analyses included randomized
treatment, and, for efficacy outcomes, the three different
models included CHADS2 score, CHA2DS2-VASc score or
the variables in the score: congestive heart failure, hypertension, age, diabetes mellitus, previous stroke or transient
ischemic attack, previous MI, peripheral arterial occlusive
disease, and female sex for efficacy endpoints. For bleeding
outcomes, the adjusted analyses included randomized treatment, HAS-BLED score or variables in the score: hypertension, age, previous stroke, previous major bleeding and
medication predisposing to bleeding for safety endpoints.
The hazard ratios (HRs) and 95% confidence intervals
(CIs), with the group with the lowest biomarker levels as
reference, were reported. Event rates were reported per 100
patient-years of follow-up. Kaplan–Meier estimates of
cumulative hazard were calculated and plotted.
Treatment effects were compared according to D-dimer
group with a Cox proportional hazard model including
treatment group, CHADS2 or HAS-BLED score,
D-dimer quartile group and treatment by D-dimer interaction as covariates. The treatments HRs are reported at
each level of D-dimer, regardless of the significance of
interaction. Adjustment for CHA2DS2-VASc score
yielded similar results (data not shown).
The interaction between VKA treatment and D-dimer
was investigated with a Cox proportional hazard model,
including treatment group, VKA treatment group,
D-dimer quartile group and VKA treatment by D-dimer
interaction as covariates.
The increased discriminative values of adding D-dimer
to models with only CHADS2, CHA2DS2-VASc or HASBLED score and study treatment were investigated by
estimating the C-index for the Cox regression models with
and without the biomarker [28]. In addition, the continuous (category-free) net reclassification improvement index
(NRI) for survival data, as described by Pencina et al.
[28], was calculated for the total group of 14 849 patients,
for the addition of D-dimer to a model with study treatment, baseline VKA treatment and one of CHADS2,
CHA2DS2-VASc or HAS-BLED score. The NRI among
event patients and among non-event patients and the
total NRI were analysed. We performed likelihood ratio
tests to evaluate whether the global model fit improved
after the addition of D-dimer.
All statistical tests were two-tailed and performed at
the 0.05 significance level. Owing to the exploratory nature of this study, the P-values were not adjusted for multiple comparisons, and should be interpreted with
caution. The statistics section at UCR conducted the statistical analyses, using the statistical software package SAS,
© 2014 International Society on Thrombosis and Haemostasis

version 9.3 for Windows (SAS Institute, Cary, NC, USA)
for all analyses.
Results
Baseline characteristics in relation to D-dimer levels at
baseline

Baseline characteristics are shown in Table 1. The group
with no VKA treatment before randomization had a
higher proportion of females, a higher rate of left ventricular dysfunction and a lower proportion of diabetes mellitus than the group receiving VKA treatment at
randomization. Only 0.78% (n = 116) of the patients had
a history of cancer. No difference was found regarding
previous stroke or CHADS2/CHA2DS2-VASc score. The
median D-dimer level was 528 lg L 1 (interquartile
range 335–878 lg L 1) in the total cohort at baseline,
and there was no difference in D-dimer levels between the
apixaban and warfarin groups. The D-dimer levels in the
no-VKA and on-VKA groups are shown in Table 2.
Higher D-dimer levels were associated with increased age,
female sex, left ventricular dysfunction and atherosclerotic
disease in both the no-VKA group and the on-VKA
group at randomization (Tables 3 and 4).
D-dimer levels at baseline in relation to thromboembolic
events and death

In the D-dimer cohort, a total of 397 patients (1.40% per
year) experienced a stroke/SEE, and 1075 (3.69% per
year) died; of these, 547 (1.88% per year) died of cardiac
causes, and 150 (0.52% per year) suffered an MI. D-dimer
levels at baseline were associated with rate of stroke/SEE
in both the no-VKA group and the on-VKA group
(Fig. 1). In the no-VKA group, the stroke/SEE rate ranged from 1.11% per year in Q1 (D-dimer ≤ 423 lg L 1)
to 1.90% per year in Q4 (D-dimer > 1123 lg L 1)
(HR [Q4 vs. Q1] 1.72, 95% CI 1.14–2.59, P = 0.003 for
association with D-dimer levels). Similar results were
found in the on-VKA group, with stroke/SEE rates of
0.74% per year in Q1 (D-dimer ≤ 289 lg L 1) and 1.32%
per year in Q4 (D-dimer > 690 lg L 1) (HR [Q4 vs.
Q1] 1.79, 95% CI 1.13–2.84, P = 0.027). After adjustment
for CHADS2 score, the association between D-dimer levels and stroke/SEE rate persisted in the no-VKA group
but not in the on-VKA group (Fig. 2). Adjustment for
CHA2DS2-VASc score attenuated the association between
D-dimer levels and stroke/SEE rate. Higher D-dimer levels
were also related to higher rates of total death (HR [Q4
vs. Q1] 4.04, 95% CI 3.06–5.33, P < 0.0001) and cardiac
death (HR 2.79, 95% CI 1.97–3.94, P < 0.0001) in the
no-VKA group. Similar results were obtained in the onVKA group (total death HR [Q4 vs. Q1] 5.50,
95% CI 4.00–7.57, P < 0.0001; cardiac death HR 5.83,
95% CI 3.62–9.39, P < 0001). These results persisted after
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Table 1 Baseline characteristics in the no-vitamin K antagonist (VKA) and on-VKA groups

Age in years (mean  SD)
Female sex, no. (%)
Male sex, no. (%)
AF, persistent or permanent, no. (%)
Calculated CrCl (mL min 1), median (Q1–Q3)
Risk factors, no. (%)
Congestive HF/LVEF ≤ 40%
Age ≥ 75 years
Hypertension
Diabetes mellitus
Prior stroke or TIA
Prior MI
PAOD
CHADS2 score, no. (%)
0–1
2
≥3
CHA2DS2-VASc score, no. (%)
0–1
2
3
4
≥5
HAS-BLED score, no. (%)
0–1
2
≥3
Medical treatment at baseline, no. (%)
Subcutaneous/intravenous heparin within the last week*
Aspirin
Clopidogrel
ACE inhibitor or ARB
b-Blocking agent
Calcium channel blocking agent
Amiodarone
Digoxin

No VKA (n = 6867)

On VKA (n = 7982)

68.5  9.8
2666 (38.8)
4201 (61.2)
5708 (83.1)
72.6 (56.0–92.9)

69.4  9.3
2618 (32.8)
5364 (67.2)
6889 (86.3)
75.5 (57.5–98.0)

2727
1978
6087
1587
1253
842
320

2619
2561
6923
2078
1531
1066
406

(39.7)
(28.8)
(88.6)
(23.1)
(18.2)
(12.3)
(4.7)

(32.8)
(32.1)
(86.7)
(26.0)
(19.2)
(13.4)
(5.1)

Total (n = 14 878)
69.0
5291
9587
12622
74.2
5353
4553
13 033
3676
2788
1914
727

 9.6
(35.6)
(64.4)
(84.9)
(56.8–95.4)
(36.0)
(30.6)
(87.6)
(24.7)
(18.7)
(12.9)
(4.9)

2266 (33.0)
2505 (36.5)
2096 (30.5)

2769 (34.7)
2860 (35.8)
2353 (29.5)

5046 (33.9)
5371 (36.1)
4461 (30.0)

598
1435
1737
1528
1569

699
1658
2122
1758
1745

1299
3099
3863
3294
3323

(8.7)
(20.9)
(25.3)
(22.3)
(22.8)

(8.8)
(20.8)
(26.6)
(22.0)
(21.9)

(8.7)
(20.8)
(26.0)
(22.1)
(22.3)

3150 (45.9)
2507 (36.5)
1210 (17.6)

2351 (29.5)
3070 (38.5)
2561 (32.1)

5503 (37.0)
5590 (37.6)
3785 (25.4)

454
3622
160
2014
4145
1931
948
2165

269
1566
102
2313
5248
2599
763
2654

723
4599
262
4337
9415
4539
1712
4830

(6.6)
(44.0)
(2.3)
(29.3)
(60.4)
(28.1)
(13.8)
(31.5)

(3.4)
(19.6)
(1.3)
(29.0)
(65.7)
(32.6)
(9.6)
(33.2)

(4.9)
(30.9)
(1.8)
(29.2)
(63.3)
(30.5)
(11.5)
(32.5)

ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CrCl, creatinine clearance; HF/LVEF, heart
failure/left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial occlusive disease; SD, standard deviation; TIA,
transient ischemic attack. *At least one dose of heparin within the last week.

Table 2 Description of the D-dimer levels at baseline in the no-vitamin K antagonist (VKA) and on-VKA groups
D-dimer
1

Mean (lg L ) (SD)
Median (lg L 1) (interquartile range)
10th–90th percentiles (lg L 1)
Range (lg L 1)
D-dimer > 500 lg L 1 (%)

No-VKA group (n = 6867)

On-VKA group (n = 7982)

P-value

1053 (1193)
665 (423–1123)
299–2097
54–7000
66

649 (806)
432 (289–690)
206–1149
6–7000
42

< 0.0001
< 0.0001

SD, standard deviation.

adjustment for CHADS2 score and study treatment in both
the no-VKA group and the on-VKA group (Fig. 2), and
also after adjustment for CHA2DS2-VASc score or the
variables included in the score (data not shown). The MI
rate was low, and no association was found with D-dimer
levels in the no-VKA group. In the on-VKA group, the MI

rate ranged from 0.35% per year in Q1 to 1.00% per year
in Q4 (HR [Q4 vs. Q1] 2.50, 95% CI 1.34–4.68, P = 0.002
after adjustment for CHADS2 score and treatment)
(Fig. 2). These results persisted after adjustment for
CHA2DS2-VASc score or the variables included in the
score (data not shown).
© 2014 International Society on Thrombosis and Haemostasis
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Table 3 Baseline characteristics according to D-dimer quartiles in the no-vitamin K antagonist group
D-dimer (lg L 1)

Age in years (mean  SD)
Female sex, no. (%)
Male sex, no. (%)
AF, persistent or permanent, no. (%)
Risk factors, no. (%)
Congestive HF/LVEF ≤ 40%
Age ≥ 75 years
Hypertension
Diabetes mellitus
Prior stroke or TIA
Prior MI
PAOD
CHADS2 score, no. (%)
0–1
2
≥3
CHA2DS2-VASc score, no. (%)
0–1
2
3
4
≥5
HAS-BLED score, no. (%)
0–1
2
≥3

≤ 423 (n = 1719)

> 423–665 (n = 1718)

> 665–1123 (n = 1717)

> 1123 (n = 1713)

P-value

62.9
480
1239
1393

(9.54)
(27.9)
(72.1)
(81.0)

67.7
673
1045
1418

(8.91)
(39.2)
(60.8)
(82.6)

70.5
743
974
1426

(8.80)
(43.3)
(56.7)
(83.1)

72.8
770
943
1471

(9.16)
(45.0)
(55.0)
(85.9)

< 0.0001
< 0.0001

635
180
1527
396
288
173
49

(36.9)
(10.5)
(88.8)
(23.0)
(16.8)
(10.1)
(2.9)

679
397
1538
426
307
209
71

(39.5)
(23.1)
(89.5)
(24.8)
(17.9)
(12.2)
(4.1)

681
594
1522
406
307
233
76

(39.7)
(34.6)
(88.6)
(23.6)
(17.9)
(13.6)
(4.4)

732
807
1500
359
351
227
124

(42.7)
(47.1)
(87.6)
(21.0)
(20.5)
(13.3)
(7.2)

0.0071
< 0.0001
0.34
0.0576
0.0341
< 0.0001
< 0.0001

< 0.0001

755 (43.9)
560 (32.6)
404 (23.5)

574 (33.4)
648 (37.7)
496 (28.9)

536 (31.2)
632 (36.8)
549 (32.0)

401 (23.4)
665 (38.8)
647 (37.8)

< 0.0001

302
530
384
271
232

138
363
490
370
357

95
312
463
406
441

63
230
400
481
539

(3.7)
(13.4)
(23.4)
(28.1)
(31.5)

< 0.0001

648 (37.8)
682 (39.8)
383 (22.4)

< 0.0001

(17.6)
(30.8)
(22.3)
(15.8)
(13.5)

987 (57.4)
520 (30.3)
212 (12.3)

(8.0)
(21.1)
(28.5)
(21.5)
(20.8)

787 (45.8)
655 (38.1)
276 (16.1)

(5.5)
(18.2)
(27.0)
(23.6)
(25.7)

728 (42.4)
650 (37.9)
339 (19.7)

AF, atrial fibrillation; HF/LVEF, heart failure/left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial occlusive
disease; SD, standard deviation; TIA, transient ischemic attack. P-value by chi-square test for categorical variables and Kruskal–Wallis test for
continuous variables.

D-dimer levels in relation to CHADS2/CHA2DS2-VASc score
for risk stratification of thromboembolic events and death

The annual rates of stroke/SEE and death increased both
with CHADS2 score and with D-dimer levels in the
no-VKA group, and a similar trend was found in the onVKA group. The C-index values for D-dimer level alone
were 0.587 and 0.567 in the no-VKA group and the onVKA group, respectively (Table S1). After addition of
D-dimer level to the CHADS2 score, the C-index
increased from 0.600 to 0.618 in the on-VKA group. The
C-index was higher in the no-VKA group, where the
event rate was higher, but the improvement with addition
of D-dimer level was somewhat smaller, the C-index
increasing from 0.646 to 0.655. The model improved significantly only in the no-VKA group. With regard to the
prediction of death, the C-index values for D-dimer level
alone were 0.636 and 0.670 in the no-VKA group and the
on-VKA group, respectively. With regard to prediction of
cardiovascular death, the C-index for D-dimer level was
higher in the on-VKA group (0.675) than in the no-VKA
group (0.600). The addition of D-dimer level to the
CHADS2 score improved the C-index most in the onVKA group, from 0.588 to 0.685, but also in the noVKA group, from 0.598 to 0.662. When D-dimer level
© 2014 International Society on Thrombosis and Haemostasis

was added to the CHA2DS2-VASc score, a similar
improvement in the prediction of stroke/SEE and death
was noted. The NRI was 11% for stroke/SEE: 18%
among event patients, and
7% among non-event
patients. The NRI was 46% for death: 24% among event
patients, and 22% among non-event patients (Table S1).
D-dimer levels in relation to efficacy of randomized
treatment for thromboembolic events

The benefits of apixaban as compared with warfarin
regarding stroke/SEE were similar through D-dimer quartiles, both in the no-VKA group and in the on-VKA
group. Accordingly, higher D-dimer levels tended to be
associated with a larger absolute gain in stroke/SEE benefit with apixaban than with warfarin, even after adjustments for CHADS2 score (Fig. 3). Also the benefits with
apixaban compared to warfarin regarding total death and
cardiac death were similar over the range of D-dimer
levels (Fig. 3).
D-dimer levels at baseline and bleeding outcomes

Major bleeds occurred in 647 patients (2.61% per year) and
1276 patients had a major/clinically relevant non-major
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Table 4 Baseline characteristics according to D-dimer quartiles in the on-vitamin K antagonist group
D-dimer (lg L 1)

Age in years (mean  SD)
Female sex, no. (%)
Male sex, no. (%)
AF, persistent or permanent, no. (%)
Risk factors, no. (%)
Congestive HF/LVEF ≤ 40%
Age ≥ 75 years
Hypertension
Diabetes mellitus
Prior stroke or TIA
Prior MI
PAOD
CHADS2 score, no. (%)
0–1
2
≥3
CHA2DS2-VASc score, no. (%)
0–1
2
3
4
≥5
HAS-BLED score, no. (%)
0–1
2
≥3

≤ 289 (n = 2004)

> 289–432 (n = 1990)

> 432–690 (n = 1995)

> 690 (n = 1993)

P-value

64.0
517
1487
1722

(9.13)
(25.8)
(74.2)
(85.9)

68.8
650
1340
1693

(8.54)
(32.7)
(67.3)
(85.1)

71.6
743
1252
1727

(8.18)
(37.2)
(62.8)
(86.6)

73.3
708
1285
1747

(8.78)
(35.5)
(64.5)
(87.7)

< 0.0001
< 0.0001

591
252
1715
515
344
205
62

(29.5)
(12.6)
(85.6)
(25.7)
(17.2)
(10.2)
(3.1)

604
539
1734
535
398
261
69

(30.4)
(27.1)
(87.1)
(26.9)
(20.0)
(13.1)
(3.5)

654
796
1747
516
371
279
113

(32.8)
(39.9)
(87.6)
(25.9)
(18.6)
(14.0)
(5.7)

770
974
1727
512
418
321
162

(38.6)
(48.9)
(86.7)
(25.7)
(21.0)
(16.1)
(8.1)

< 0.0001
< 0.0001
0.2813
0.7972
0.0136
< 0.0001
< 0.0001

0.1109

938 (46.8)
654 (32.6)
412 (20.6)

738 (37.1)
668 (33.6)
584 (29.3)

596 (29.9)
781 (39.1)
618 (31.0)

497 (24.9)
757 (38.0)
739 (37.1)

< 0.0001

379
598
505
293
229

164
418
573
432
403

86
375
545
470
519

70
267
499
563
594

(3.5)
(13.4)
(25.0)
(28.2)
(29.8)

< 0.0001

472 (23.7)
773 (38.8)
748 (37.5)

< 0.0001

(18.9)
(29.8)
(25.2)
(14.6)
(11.4)

840 (41.9)
715 (35.7)
449 (22.4)

(8.2)
(21.0)
(28.8)
(21.7)
(20.3)

587 (29.5)
770 (38.7)
633 (31.8)

(4.3)
(18.8)
(27.3)
(23.6)
(26.0)

452 (22.7)
812 (40.7)
731 (36.6)

AF, atrial fibrillation; HF/LVEF, heart failure/left ventricular ejection fraction; MI, myocardial infarction; PAOD, peripheral arterial occlusive
disease; SD, standard deviation; TIA, transient ischemic attack. P-value by chi-square test for categorical variables and Kruskal–Wallis test for
continuous variables.

bleed (5.05% per year) during the median follow-up of
1.9 years. Higher D-dimer levels were significantly associated with increased risk of both major and major/clinically
relevant non-major bleeds, regardless of VKA treatment status at baseline (Fig. 4). In the no-VKA group, the rate of
major bleeds ranged from 1.61% per year in Q1 (D-dimer <
423 lg L 1) to 2.45% per year in Q4 (D-dimer > 1123 lg
L 1) (HR [Q4 vs. Q1] 2.17, 95% CI 1.55–3.04, P < 0.0001
after adjustment for HAS-BLED score). Similar results were
obtained in the on-VKA group (HR [Q4 vs. Q1] 1.97,
95% CI 1.44–2.69, P < 0.0001) (Fig. 2). Similar results
were also found after adjustment for the variables included
in the score (data not shown).
D-dimer levels in relation to HAS-BLED score for risk
stratification of bleeding

The annual risk of major bleeds increased with both
HAS-BLED score and D-dimer quartiles. In the no-VKA
group, the rates of major bleeds were 1.16% per year in
the group with HAS-BLED 0–1 and D-dimer Q1, and
4.94% per year in the group with HAS-BLED ≥ 3 and
D-dimer Q4. Similar results were obtained in the onVKA group: 1.09% per year in the group with
HAS-BLED 0–1 and D-dimer Q1, and 5.03% per year in

the group with HAS-BLED ≥ 3 and D-dimer Q4. The
C-index values for D-dimer for major bleeds were 0.621
and 0.587 in the no-VKA group and the on-VKA group,
respectively. Adding D-dimer level to the HAS-BLED
score improved the predictive model for major bleeds
from 0.610 to 0.641 in the no-VKA group and from
0.618 to 0.635 in the on-VKA group. The NRI was 28%
for major bleed: 5% among event patients, and 23%
among non-event patients (Table S1).
D-dimer levels in relation to efficacy of randomized
treatment for bleeding events

There was no significant interaction between D-dimer levels and randomized treatment with respect to bleeding
events. Even after adjustment for HAS-BLED score and
VKA status at randomization, apixaban treatment was
associated with consistent reductions in the rates of major
bleeds and major bleeds/clinically relevant non-major
bleeds over the range of D-dimer levels. In the no-VKA
group, the rates of major bleeds were 3.21% per year in
the apixaban-randomized patients and 4.92% per year
in
the
warfarin-randomized
patients
in
Q4
(D-dimer > 1123 lg L 1) (HR 0.66, 95% CI 0.45–0.97).
In the on-VKA group, the HR for apixaban vs. warfarin
© 2014 International Society on Thrombosis and Haemostasis
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increase with age, female sex, heart failure, and atherosclerotic diseases. Increasing D-dimer level was gradually
related to the rates of stroke/SEE, all-cause death, cardiac
death, and major bleeds. Ongoing treatment with warfarin
was associated with lower D-dimer levels, but the relationships with patient characteristics were observed both in
patients without and those with anticoagulant treatment.
The predictive values of D-dimer level alone for death and
major bleeds were higher than those of the clinical risk
scores. Adding D-dimer to the CHADS2, CHA2DS2-VASc
and HAS-BLED scores improved the prediction of thromboembolic events and bleeds, respectively. The benefits of
apixaban and those of warfarin regarding stroke/SEE, allcause death, cardiac death and bleeds were not significantly
different through the range of D-dimer levels.

Primary endpoint stroke/SEE, D-dimer
Warfarin within 7 days - No

A
0.06

Group 1: ≤ 423
Group 3: > 665–1123

Group 2: > 423–665
Group 4: > 1123

Cumulative hazard rate

0.05

0.04

0.03

0.02

0.01

0.00
0

6

12

No. at risk
Group 1 1719
Group 2 1718
Group 3 1717
Group 4 1713

18

24

1317
1262
1182
1157

762
748
718
744

30

Months
1667
1631
1611
1566

1626
1591
1543
1483

366
395
404
397

Primary endpoint stroke/SEE, D-dimer
Warfarin within 7 days - Yes

B
0.06

Group 1: ≤ 289
Group 3: > 432–690

Group 2: > 289–432
Group 4: > 690

Cumulative hazard rate

0.05

0.04

0.03

0.02

0.01

0.00
0

6

12

No. at risk
Group 1 2004
Group 2 1990
Group 3 1995
Group 4 1993

18

24

1559
1482
1424
1362

837
765
762
748

30

Months

1962
1931
1915
1882

1935
1889
1870
1797

360
347
366
400

Fig. 1. Cumulative hazard rates for the primary endpoint stroke or
systemic embolism (SEE) by D-dimer quartiles at baseline before
randomization to apixaban or warfarin study treatment. (A) Novitamin K antagonist (VKA) group. (B) On-VKA group. Groups 1,
2, 3 and 4 represent D-dimer quartiles 1, 2, 3 and 4, respectively.

was 0.57 (95% CI 0.39–0.82) in D-dimer Q4 (D-dimer >
690 lg L 1) (Fig. 3).

D-dimer levels and CHADS2/CHA2DS2-VASc scores

In the present study, high D-dimer levels were related to
increased risks of stroke/SEE and all-cause death, both
total death and cardiac death. In clinical practice, risk
stratification of the AF patient is commonly performed
with risk scores, such as CHADS2/CHA2DS2-VASc,
based on clinical features. The CHADS2 score was primarily developed to estimate the risk of stroke in patients
without anticoagulant treatment, in order to support decision-making for this therapy [6]. Today, the CHADS2
score has also been found to be predictive of stroke and
of death in patients with anticoagulant treatment [10]. In
the present study, D-dimer added predictive value to the
CHADS2 and CHA2DS2-VASc scores for stroke/SEE,
and even more value concerning death. D-dimer level
alone had an even higher predictive value for death and
cardiovascular death than the clinical risk scores, whether
or not patients were receiving warfarin treatment. The
predictive value was most pronounced in the on-VKA
group, indicating that patients with high D-dimer levels
despite anticoagulant treatment have a more advanced
underlying disease that is not identified by the clinical risk
scores. Measurement of the D-dimer level is widely available as a routine method in most hospitals. Therefore, its
inclusion in a risk stratification tool for patients with AF
might be considered. However, in the real-world environment, there are many different methods for measuring
D-dimer levels and fairly large variations in the results,
including the influences of preanalytic errors at blood
sampling. Therefore, the clinical usefulness of a measurement of D-dimer level is still questionable, even though it
is recommended as a tool for risk assessment in the setting of venous thromboembolism [16].
D-dimer and risk of bleeding

Discussion
This study has verified that D-dimer levels are increased in
patients with AF and at least one risk factor for stroke,
© 2014 International Society on Thrombosis and Haemostasis

Increased D-dimer levels have been associated with bleeding and mortality risk in patients with intracerebral hemorrhage and cancer [29–31]. The D-dimer level reflects the
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Outcome
D-dimer level (µg L–1)

Number
of Patients

Stroke/systemic embolism, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Stroke/systemic embolism, on VKA
≤ 289
> 289–432
> 432–690
> 690
Death, no VKA
≤ 423
> 423–665
> 665–1123
>1123
Death, on VKA
≤ 289
> 289–432
> 432–690
> 690
Cardiac death, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Cardiac death, on VKA
≤ 289
> 289–432
> 432–690
> 690
Myocardial infarction, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Myocardial infarction, on VKA
≤ 289
> 289–432
> 432–690
> 690
Major bleed, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Major bleed, on VKA
≤ 289
> 289–432
> 432–690
> 690
Major bleed/CS non-major bleed, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Major bleed/CS non-major bleed, on VKA
≤ 289
> 289–432
> 432–690
> 690

Events
% per year

HR (95% CI)
Q group 1
as reference

1719
1718
1717
1713

37 (1.11)
51 (1.55)
72 (2.24)
60 (1.90)

1.30 (0.85–1.98)
1.79 (1.20–2.67)
1.42 (0.94–2.15)

2004
1990
1995
1993

29 (0.74)
43 (1.13)
52 (1.38)
49 (1.32)

1.43 (0.89–2.29)
1.69 (1.07–2.67)
1.54 (0.96–2.45)

1719
1718
1717
1713

63 (1.85)
95 (2.80)
175 (5.28)
243 (7.49)

1.43 (1.04–1.97)
2.62 (1.97–3.51)
3.58 (2.71–4.74)

2004
1990
1995
1993

45 (1.13)
84 (2.17)
130 (3.35)
235 (6.20)

1.82 (1.27–2.62)
2.72 (1.94–3.83)
4.83 (3.50–6.67)

1719
1718
1717
1713

44 (1.29)
50 (1.47)
113 (3.41)
117 (3.61)

1.08 (0.72–1.62)
2.41 (1.70–3.43)
2.45 (1.72–3.47)

2004
1990
1995
1993

20 (0.50)
38 (0.98)
53 (1.37)
111 (2.93)

1.84 (1.07–3.17)
2.48 (1.48–4.16)
5.04 (3.11–8.16)

1719
1718
1717
1713

11 (0.33)
13 (0.39)
15 (0.46)
18 (0.57)

1.11 (0.49–2.48)
1.24 (0.57–2.72)
1.45 (0.68–3.10)

2004
1990
1995
1993

14 (0.35)
13 (0.34)
27 (0.71)
37 (1.00)

0.91 (0.43–1.95)
1.86 (0.97–3.56)
2.50 (1.34–4.68)

1716
1711
1714
1708

50 (1.61)
64 (2.15)
88 (3.08)
109 (4.02)

1.24 (0.86–1.80)
1.71 (1.21–2.43)
2.17 (1.55–3.04)

2000
1987
1993
1991

60 (1.62)
79 (2.23)
98 (2.83)
123 (3.74)

1.24 (0.88–1.73)
1.50 (1.08–2.07)
1.97 (1.44–2.69)

1716
1711
1714
1708

109 (3.58)
129 (4.41)
150 (5.36)
178 (6.70)

1.15 (0.89–1.49)
1.35 (1.06–1.74)
1.63 (1.28–2.08)

2000
1987
1993
1991

135 (3.71)
159 (4.58)
187 (5.54)
224 (7.00)

1.14 (0.90–1.43)
1.33 (1.07–1.67)
1.67 (1.35–2.08)

P-value
Effect of
biomarker level
0.0302

0.1292

< 0.0001

< 0.0001

< 0.0001

< 0.0001

0.7844

0.0017

< 0.0001

< 0.0001

0.0004

< 0.0001

0.3

0.5 0.7
Lower risk

1

3

5

7 9

Higher risk

Fig. 2. The effect of D-dimer quartiles on study endpoints in the no-vitamin K antagonist (VKA) group and the on-VKA group. A Cox proportion model was used, with biomarker level, CHADS2/HAS-BLED score and randomized treatment as covariates. CI, confidence interval;
CS, clinically significant; HR, hazard ratio.

sum of thrombin generation and endogenous fibrin turnover, and may be a marker for increased fibrinolytic
activity [32,33]. However, in clinical practice the risk of
bleeding is estimated from clinical history and patient
characteristics, and a perceived increased bleeding risk is
often used as a reason to withhold anticoagulant treatment in AF patients [34]. The HAS-BLED score can be
evaluated in AF patients both with and without anticoagulant treatment, and predicts the risk of bleeding [8,35].

In the present study, increased D-dimer levels were
strongly related to the frequency of major and clinically
significant non-major bleeds, and added predictive value
to the HAS-BLED score to improve bleeding risk stratification. The predictive value of D-dimer level alone for
major bleeds was most pronounced in patients who had
no experience of anticoagulant treatment. In a clinical setting, where the bleeding risk has to be evaluated before
initiation of anticoagulant treatment, D-dimer seems to
© 2014 International Society on Thrombosis and Haemostasis
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Outcome
D-dimer level (µg L–1)
Stroke/systemic embolism, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Stroke/systemic embolism, on VKA
≤ 289
> 289–432
> 432–690
> 690
Death, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Death, on VKA
≤ 289
> 289–432
> 432–690
> 690
Cardiac death, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Cardiac death, on VKA
≤ 289
> 289–432
> 432–690
> 690
Myocardial infarction, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Myocardial infarction, on VKA
≤ 289
> 289–432
> 432–690
> 690
Major bleed, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Major bleed, on VKA
≤ 289
> 289–432
> 432–690
> 690
Major bleed/CS non major bleed, no VKA
≤ 423
> 423–665
> 665–1123
> 1123
Major bleed/CS non major bleed, on VKA
≤ 289
> 289–432
> 432–690
> 690

Number
of Patients

Apixaban
Warfarin
Events (% per year)

HR (95% CI)

1719
1718
1717
1713

19 (1.12)
26 (1.50)
23 (1.42)
26 (1.62)

18 (1.10)
25 (1.60)
49 (3.08)
34 (2.20)

–
1.05 (0.55–2.00)
0.93 (0.54–1.62)
0.45 (0.28–0.74)
0.76 (0.46–1.27)

2004
1990
1995
1993

16 (0.84)
22 (1.18)
27 (1.41)
20 (1.11)

13 (0.64)
21 (1.09)
25 (1.34)
29 (1.52)

1.33 (0.64–2.76)
1.08 (0.60–1.97)
1.03 (0.60–1.78)
0.73 (0.41–1.28)

1719
1718
1717
1713

38 (2.20)
46 (2.58)
75 (4.52)
116 (7.06)

25 (1.49)
49 (3.05)
100 (6.04)
127 (7.93)

1.48 (0.89–2.44)
0.85 (0.57–1.26)
0.75 (0.55–1.01)
0.90 (0.70–1.16)

2004
1990
1995
1993

23 (1.19)
39 (2.04)
63 (3.21)
115 (6.25)

22 (1.07)
45 (2.29)
67 (3.50)
120 (6.16)

1.13 (0.63–2.03)
0.90 (0.58–1.38)
0.91 (0.64–1.28)
1.01 (0.78–1.31)

1719
1718
1717
1713

26 (1.50)
24 (1.35)
51 (3.07)
55 (3.34)

18 (1.07)
26 (1.62)
62 (3.74)
62 (3.88)

1.41 (0.77–2.57)
0.83 (0.48–1.45)
0.82 (0.57–1.19)
0.88 (0.61–1.26)

2004
1990
1995
1993

12 (0.62)
17 (0.89)
22 (1.12)
51 (2.77)

8 (0.39)
21 (1.07)
31 (1.62)
60 (3.08)

1.63 (0.67–3.99)
0.84 (0.44–1.59)
0.68 (0.39–1.18)
0.91 (0.63–1.32)

1719
1718
1717
1713

3 (0.18)
9 (0.51)
7 (0.43)
8 (0.50)

8 (0.49)
4 (0.25)
8 (0.49)
10 (0.64)

0.36 (0.10–1.37)
2.02 (0.62–6.57)
0.87 (0.32–2.41)
0.80 (0.31–2.02)

2004
1990
1995
1993

7 (0.37)
4 (0.21)
11 (0.57)
21 (1.17)

7 (0.34)
9 (0.46)
16 (0.86)
16 (0.84)

1.07 (0.38–3.06)
0.46 (0.14–1.49)
0.66 (0.31–1.42)
1.37 (0.72–2.63)

1719
1718
1717
1713

18 (1.13)
29 (1.84)
38 (2.63)
46 (3.21)

32 (2.10)
35 (2.51)
50 (3.54)
63 (4.92)

0.54 (0.30–0.96)
0.72 (0.44–1.18)
0.76 (0.50–1.16)
0.66 (0.45–0.97)

2004
1990
1995
1993

24 (1.33)
38 (2.18)
42 (2.39)
46 (2.83)

36 (1.89)
41 (2.28)
56 (3.29)
77 (4.63)

0.67 (0.40–1.13)
0.88 (0.56–1.36)
0.71 (0.48–1.06)
0.57 (0.39–0.82)

1719
1718
1717
1713

42 (2.70)
62 (3.99)
57 (3.99)
73 (5.21)

67 (4.51)
67 (4.88)
93 (6.78)
105 (8.38)

0.61 (0.41–0.90)
0.80 (0.56–1.13)
0.60 (0.43–0.84)
0.62 (0.46–0.84)

2004
1990
1995
1993

46 (2.57)
72 (4.21)
86 (5.02)
89 (5.58)

89 (4.81)
87 (4.95)
101 (6.08)
135 (8.40)

0.52 (0.37–0.75)
0.80 (0.58–1.09)
0.81 (0.61–1.08)
0.63 (0.49–0.83)

P-value for
interaction
0.1243

0.5995

0.1482

0.8842

0.4710

0.4297

0.2582

0.2933

0.8166

0.5207

0.6338

0.1905

0.1

0.3

0.5 0.7 1

Favor apixaban

3

5

7

Favor warfarin

Fig. 3. The efficacy of apixaban vs. warfarin for quartiles of D-dimer levels at baseline separated into the group with no vitamin K antagonist
(VKA) treatment and the group receiving VKA treatment before randomization to study treatment. A Cox proportion model was used, with
biomarker level, CHADS2/HAS-BLED score, treatment and interaction between treatment and biomarker level as covariates. CI, confidence
interval; CS, clinically significant; HR, hazard ratio.

be a better tool than HAS-BLED score, which includes
risk factors such as previous experience of warfarin.
D-dimer levels and benefit of apixaban

Apixaban was superior to warfarin regarding the risk of
stroke and reduced the frequency of bleeding in the
ARISTOTLE trial [5]. The relative benefits of apixaban
vs. warfarin have been shown consistently across all
CHADS2, CHA2DS2-VASc and HAS-BLED scores, even
though the relative risk reduction for intracranial bleeding tended to be higher in patients with a HAS-BLED
score of ≥ 3 [9]. The relative benefits of apixaban vs.
warfarin were not significantly different between D-dimer
quartiles.
© 2014 International Society on Thrombosis and Haemostasis

Limitations

The cut-off of D-dimer level for use in risk stratification in
patients with AF has not been defined. In this study, we
used the quartiles of D-dimer, and the optimal D-dimer level
in AF has to be further investigated and prospectively validated. The INR value in the on-VKA group before randomization and the percent time in therapeutic INR range before
randomization to study treatment were not known, and their
relationships with D-dimer levels could not be estimated.
Conclusion
In conclusion, a high D-dimer level is associated with
increased risks of stroke, death, and bleeding, and has
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Addendum

Major bleed, D-dimer
Warfarin within 7 days–No

A
0.10

Group 1: ≤ 423
Group 3: > 665–1123

Group 2: > 423–665
Group 4: > 1123

0.09

Cumulative hazard rate

0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0.00
0

6

12

18

24

1198
1097
1030
955

691
649
605
602

30

Months
No at risk
Group 1 1716
Group 2 1711
Group 3 1714
Group 4 1708

1572
1496
1467
1388

1479
1395
1356
1256

321
348
327
317

Major bleed, D-dimer
Warfarin within 7 days–Yes

B
0.10

Group 1: ≤ 289
Group 3: > 432–690

Group 2: > 289–432
Group 4: > 690

Acknowledgements

0.09
0.08
Cumulative hazard rate

L. Wallentin, J. H. Alexander, C. B. Granger, J. Ansell,
B. J. Gersh, M Hanna, J. D. Horowitz, and E. M. Hylek
contributed substantially to the design of the ARISTOTLE trial as members of the Executive Committee. R.
D. Lopes and E. M. Hylek contributed substantially to
the performance of the trial as members of the Clinical
Events Committee. C. Christersson, L. Wallentin, J. H.
Alexander, C. B. Granger, M. Hanna, J. D. Horowitz, B.
J. Gersh, A. Siegbahn, R. D. Lopes, and E. M. Hylek
substantially contributed to the design of the
ARISTOTLE Biomarker substudy as members of the
ARISTOLE Biomarker substudy Committee. C. Christersson, K. Huber, S. Husted, and R. De Caterina contributed to the acquisition of data as ARISTOTLE
investigators. A. Siegbahn responsible for the plasma
measurements of D-dimer at the UCR laboratory. U. Andersson performed the statistical analyses. C. Christersson
and A. Siegbahn provided the first draft of the manuscripts. All authors participated in the interpretation of
data, critically revised the manuscript, and approved the
final version of the manuscript.

U. N€
assander Schikan and M. Tillberg, at UCR, Uppsala,
Sweden, provided editorial assistance.

0.07
0.06
0.05

Disclosure of Conflict of Interests

0.04

B. J. Gersh reports receiving personal fees from Medtronic. Inc., Baxter Healthcare Corporation, the Cardiovascular Research Foundation, Merck & Co. Inc., St Jude
Medical, Ortho-McNeil Janssen Scientific Affairs, TEVA
Pharmaceuticals, and Boston Scientific, outside the submitted work. C. B. Granger reports receiving grants and
personal fees from Bristol Myers Squibb, Pfizer, Daiichi,
and Boehringer Ingelheim, as well as personal fees from
Janssen, during the conduct of the study. C. B. Granger
also reports receiving grants and personal fees from Glaxo
SmithKline, Sanofi-Aventis, Takeda, and The Medicine’s
Company; personal fees from Hoffmann-La Roche, Lilly,
Ross Medical Corporation, Salix Pharmaceuticals, and
Astra Zeneca; and grants from the Medtronic Foundation
and Merck & Co., outside the submitted work. E. M.
Hylek reports receiving personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo,
Janssen, Pfizer, and Roche, outside the submitted work. J.
Ansell reports receiving personal fees from Bristol Myers
Squibb, Pfizer, Janssen, Boehringer Ingelheim, and Daiichi Sankyo, outside the submitted work. J. H. Alexander
reports receiving personal fees and grants from BristolMyers Squibb and Pfizer, during the conduct of the study,

0.03
0.02
0.01
0.00
0

6

12

18

24

1432
1333
1265
1166

790
693
687
634

30

Months
No at risk
Group 1 2000
Group 2 1987
Group 3 1993
Group 4 1991

1867
1823
1786
1718

1789
1719
1684
1557

339
314
320
327

Fig. 4. Cumulative hazard rates of major bleeds in relation to
D-dimer quartiles at baseline before randomization to apixaban or
warfarin study treatment. (A) No-vitamin K antagonist (VKA)
group. (B) On-VKA group. Groups 1, 2, 3 and 4 represent D-dimer
quartiles 1, 2, 3 and 4, respectively.

an additional predictive value to clinical risk scores in
patients with AF. There was no interaction between the
D-dimer level at entry and the benefits of apixaban
vs. warfarin for reduction of stroke, mortality, and
bleeding.

© 2014 International Society on Thrombosis and Haemostasis

D-dimer for risk assessment in atrial fibrillation 1411

and personal fees from Boehringer Ingelheim, Bayer, and
Ortho-McNeil-Janssen, outside the submitted work. L.
Wallentin reports receiving grants and personal fees from
Bristol-Myers Squibb and Pfizer, during the conduct of
the study. L. Wallentin also reports receiving grants and
personal fees from AstraZeneca, Boehringer-Ingelheim,
GlaxoSmithKline, and Merck & Co., and personal fees
from Abbott, Athera Biotechnologies, and Regado Biosciences, outside the submitted work. M. Hanna is an
Executive Medical Director at Bristol-Myers Squibb
(BMS), the sponsor of the work described in the present
article. Additionally, M. Hanna is the Medical Lead for
the apixaban development program, and was the atrial
fibrillation lead and sponsor’s study director/central medical monitor for the ARISTOTLE study, the trial that generated the data in the present article. Salary compensation
is received for his position from Bristol-Myers Squibb. R.
De Caterina reports receiving grants and personal fees
from Boehringer-Ingelheim, Bayer, Bristol-Myers Squibb,
and Daiichi-Sankyo, and personal fees from Roche, outside the submitted work. R. D. Lopes reports receiving
grants and personal fees from Bristol-Myers Squibb, and
personal fees from Pfizer and Boehringer Ingleheim, during the conduct of the study. R. D. Lopes also reports
receiving grants and personal fees from Bristol-Myers
Squibb; grants from Glaxo Smith Kline; and personal fees
from Bayer, Boehringer Ingleheim, and Pfizer, outside the
submitted work. S. Husted reports receiving grants and
personal fees from Pfizer and Bristol-Myers Squibb, during the conduct of the study. S. Husted also reports
receiving grants and personal fees from Bayer, Boehringer-Ingelheim, and AstraZeneca, and grants from GlaxoSmithKline, outside the submitted work. U. Andersson
reports receiving grants from UCR, during the conduct of
the study. A. Siegbahn reports receiving grants from Bristol-Myers Squibb, AstraZeneca, and Boehringer-Ingelheim, outside the submitted work. The other authors state
that they have no conflict of interest.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. The discriminative value of D-dimer levels as
compared with risk scores.
References
1 Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel
WB, Levy D. Impact of atrial fibrillation on the risk of
death: the Framingham Heart Study. Circulation 1998; 98:
946–52.
2 Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence,
incidence, prognosis, and predisposing conditions for atrial
fibrillation: population-based estimates. Am J Cardiol 1998; 82:
2N–9N.

© 2014 International Society on Thrombosis and Haemostasis

3 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic
therapy to prevent stroke in patients who have nonvalvular atrial
fibrillation. Ann Intern Med 2007; 146: 857–67.
4 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J,
Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S,
Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener
HC, Joyner CD, Wallentin L, Committee R-LS, Investigators.
Dabigatran versus warfarin in patients with atrial fibrillation. N
Engl J Med 2009; 361: 1139–51
5 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek
EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A,
Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia
D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. Apixaban
versus warfarin in patients with atrial fibrillation. N Engl J Med
2011; 365: 981–92.
6 Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK,
Singer DE. Comparison of risk stratification schemes to predict
thromboembolism in people with nonvalvular atrial fibrillation. J
Am Coll Cardiol 2008; 51: 810–15.
7 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining
clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based
approach: the euro heart survey on atrial fibrillation. Chest 2010;
137: 263–72.
8 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip
GY. A novel user-friendly score (HAS-BLED) to assess 1-year
risk of major bleeding in patients with atrial fibrillation: the Euro
Heart Survey. Chest 2010; 138: 1093–100.
9 Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit
MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz
JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek
EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according
to patient risk of stroke and of bleeding in atrial fibrillation: a
secondary analysis of a randomised controlled trial. Lancet 2012;
380: 1749–58.
10 Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ. Risks for stroke, bleeding, and death in
patients with atrial fibrillation receiving dabigatran or warfarin
in relation to the CHADS2 score: a subgroup analysis of the
RE-LY trial. Ann Intern Med 2011; 155: 660–7.
11 Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298–
307.
12 Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD,
Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S,
Wallentin L. Cardiac biomarkers are associated with an
increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation
Therapy (RE-LY) substudy. Circulation 2012; 125: 1605–16.
13 Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D,
McBane RD. Predicting left atrial thrombi in atrial fibrillation.
Am Heart J 2010; 159: 665–71.
14 Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and
peptides. Blood Rev 1990; 4: 25–40.
15 Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, Coccheri S. Predictive value of D-dimer test for
recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in
carriers of congenital thrombophilia. Circulation 2003; 108:
313–18.
16 Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker

1412 C. Christersson et al

17

18

19

20

21

22

23

24

25

SG, Makdissi R, Guyatt GH. Diagnosis of DVT: antithrombotic
therapy and prevention of thrombosis, 9th ed: American College
of Chest Physicians evidence-based clinical practice guidelines.
Chest 2012; 141: e351S–418S.
Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach
J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer
and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and
Thrombosis Study. J Clin Oncol 2009; 27: 4124–9.
Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J.
Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47–51.
Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD,
Beevers DG. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation.
Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425–31.
Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H,
Hasegawa D, Matsuda O. Prediction of left atrial appendage
thrombi in non-valvular atrial fibrillation. Eur Heart J 2007; 28:
2217–22.
Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of
thrombogenesis in chronic atrial fibrillation: effects of warfarin
treatment. Br Heart J 1995; 73: 527–33.
Mahe I, Drouet L, Chassany O, Mazoyer E, Simoneau G, Knellwolf AL, Caulin C, Bergmann JF. D-dimer: a characteristic of
the coagulation state of each patient with chronic atrial fibrillation. Thromb Res 2002; 107: 1–6.
Nakatani Y, Mizumaki K, Nishida K, Hirai T, Sakabe M, Oda
Y, Joho S, Fujiki A, Nozawa T, Inoue H. Anticoagulation control quality affects the D-dimer levels of atrial fibrillation
patients. Circ J 2012; 76: 317–21.
Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases
coagulation activity in patients with acute deep vein thrombosis.
Thromb Haemost 2011; 105: 181–9.
Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y,
Mohan P, Wang J, Harrington RA, Wallentin LC. Effect of
apixaban, an oral and direct factor Xa inhibitor, on coagulation
activity biomarkers following acute coronary syndrome. Thromb
Haemost 2010; 104: 976–83.

26 Schulman S, Kearon C. Definition of major bleeding in clinical
investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–4.
27 Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek
EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for
reduction in stroke and other ThromboemboLic events in atrial
fibrillation (ARISTOTLE) trial: design and rationale. Am Heart
J 2010; 159: 331–9.
28 Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS.
Evaluating the added predictive ability of a new marker: from
area under the ROC curve to reclassification and beyond. Stat
Med 2008; 27: 157–72; discussion 207–12.
29 Kim DY, Lee JH, Kim SD, Lim SN, Choi Y, Lee YS, Kang
YA, Seol M, Jeon M, Kim JY, Lee KH, Lee YJ. Significance of
fibrinogen, D-dimer, and LDH levels in predicting the risk of
bleeding in patients with acute promyelocytic leukemia. Leuk
Res 2011; 35: 152–8.
30 Chiu CC, Li YN, Lin LJ, Hsiao CT, Hsiao KY, Chen IC. Serum
D-dimer as a predictor of mortality in patients with acute
spontaneous intracerebral hemorrhage. J Clin Neurosci 2012; 19:
810–13.
31 Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O. Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer
patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost 2012; 10: 2027–31.
32 Bates SM. D-dimer assays in diagnosis and management of
thrombotic and bleeding disorders. Semin Thromb Hemost 2012;
38: 673–82.
33 Ozolina A, Strike E, Jaunalksne I, Krumina A, Bjertnaes LJ,
Vanags I. PAI-1 and t-PA/PAI-1 complex potential markers of
fibrinolytic bleeding after cardiac surgery employing cardiopulmonary bypass. BMC Anesthesiol 2012; 12: 27.
34 Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal
atrial fibrillation: report from the Stockholm Cohort of Atrial
Fibrillation. Eur Heart J 2010; 31: 967–75.
35 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678
patients with atrial fibrillation: the Swedish Atrial Fibrillation
cohort study. Eur Heart J 2012; 33: 1500–10.

© 2014 International Society on Thrombosis and Haemostasis

